Open AccessLate‐onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios
Author(s) -
Marelli Cecilia,
Gutierrez LaureAnne,
Menjot de Champfleur Nicolas,
Charroud Celine,
De Verbizier Delphine,
Touchon Jacques,
Douillet Patrice,
Berr Claudine,
Lehmann Sylvain,
Gabelle Audrey
Publication year - 2015
Publication title -
alzheimer's and dementia: diagnosis, assessment and disease monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.497
H-Index - 37
ISSN - 2352-8729
DOI - 10.1016/j.dadm.2015.06.004
Subject(s) - frontotemporal lobar degeneration , cerebrospinal fluid , biomarker , medicine , frontotemporal dementia , pathology , alzheimer's disease , tau protein , disease , oncology , dementia , biology , genetics
Cerebrospinal fluid (CSF) biomarker ratios were never evaluated in late‐onset (>65 years) behavioral variant of frontotemporal lobar degeneration (bvFTLD) versus Alzheimer's disease (AD). Methods A retrospective monocentric study on 44 clinically suspected amnestic AD or bvFTLD patients with onset after 65 years and available CSF and clinical data. Results The final clinical diagnosis was AD (n = 28; 64%), late‐onset bvFTLD (n = 14; 32%), and others (n = 2; 4%). Applying the CSF cutoff total‐tau/Aβ 1–42 of 1.06, all the bvFTLD were in the FTLD range (<1.06, bvFTLD/FTLD), whereas the AD patients were either in the AD (>1.06, AD/AD) or in the FTLD range (<1.06, AD/FTLD); CSF biomarkers were significantly different in these three groups, but not neuroradiological features or presence of episodic memory deficit. Discussion Late‐onset bvFTLD is underdiagnosed. The available CSF biomarker ratio cutoff need further improvement and overestimated late‐onset bvFTLD but could potentially differentiate it from AD, notably in case of conflicting results.